Research Report on Abbott India Ltd. on the basis of Company Profile, Management, Shareholding Pattern, SWOT Analysis, Competitive Analysis, and Way forward.
Here is a deep explanation of Patanjali's product mix. Also, giving a brief regarding what the product mix is.
*For creating any presentation like this, mail me on jindalmuskn341@gmail.com .*
Here is a deep explanation of Patanjali's product mix. Also, giving a brief regarding what the product mix is.
*For creating any presentation like this, mail me on jindalmuskn341@gmail.com .*
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
"Study on factors influencing capability and usability of Consumers Durables-LG Brand shop MOT [Moment Of
Truth] on Consumer Behaviour"says the various Moment of Truth that the Customer encounter when entering into the brand shop .
Various Moment of Truth that the customer encounters are
Visual Merchandising or Point of Display over the products, Employee Behaviour with theCustomers and after that Measuring the Customer Satisfaction that Customer get after interactingwith the Moment of truth they encounter.
The main Objective of the given project was to study the impact of MOT [Moment of Truth] on Customer Buying Behaviour and observing SSE‘s [Shop Sales Executives] Behaviour in dealing with Customers and also analyzing and measuring the Customer Satisfaction and Experience.
This project basically deals with the Evaluation of Individual Brand shop of LG on the basis of MOT [Moment Of Truth] and Shop Sales Executives behavioural aspects.
It is a marketing presentation on the FMCG sector company MDH PVT. LTD. which tells about the company profile, its market, CSR activities, and its future scope.
Over the last two decades, Tata Salt has lived up to its claim of being 'Desh Ka Namak'. As of January, 2016, more than 70,000 metric tonnes of Tata Salt is sold through over 16.6 lakh retail outlets reaching 135 million households across the country each month. The brand has managed to achieve these robust figures by consistently delivering health-aware products. The key to the brand's success lies in the superior product quality of Tata Salt.
The biocon pharmaceutical ppt is majorly focused on the background, the history and revenue, EBITDA, number of employees working, the segment, turnover of the company of FY16 and SWOT analysis.
Aarti Drugs Limited (ADL), incorporated in 1984 is part of Rs 3,000 crore Aarti Group of
Industries and is engaged in manufacturing and sale of Active pharmaceutical ingredients
(APIs), advanced intermediates and specialty chemicals. ADL manufactures drugs in
therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, sedatives,
anti-depressant, anti-diarrhea and anti-inflammatory.
In Aarti Drugs we get a bulk drugs manufacturer with steady growth across the years,
continuously improving performance on various financial parameters, good dividend
yield of more than 5% and low valuations of 5 times earnings and EV/EBIT of 5.28.
Besides, what instills further confidence in the stock is the fact that promoters of the
company have been continuously increasing their stake with regular purchases from open
market. Two years back promoters had 54.83% stake in the company and the same now
stands increased to 59.65%.
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
"Study on factors influencing capability and usability of Consumers Durables-LG Brand shop MOT [Moment Of
Truth] on Consumer Behaviour"says the various Moment of Truth that the Customer encounter when entering into the brand shop .
Various Moment of Truth that the customer encounters are
Visual Merchandising or Point of Display over the products, Employee Behaviour with theCustomers and after that Measuring the Customer Satisfaction that Customer get after interactingwith the Moment of truth they encounter.
The main Objective of the given project was to study the impact of MOT [Moment of Truth] on Customer Buying Behaviour and observing SSE‘s [Shop Sales Executives] Behaviour in dealing with Customers and also analyzing and measuring the Customer Satisfaction and Experience.
This project basically deals with the Evaluation of Individual Brand shop of LG on the basis of MOT [Moment Of Truth] and Shop Sales Executives behavioural aspects.
It is a marketing presentation on the FMCG sector company MDH PVT. LTD. which tells about the company profile, its market, CSR activities, and its future scope.
Over the last two decades, Tata Salt has lived up to its claim of being 'Desh Ka Namak'. As of January, 2016, more than 70,000 metric tonnes of Tata Salt is sold through over 16.6 lakh retail outlets reaching 135 million households across the country each month. The brand has managed to achieve these robust figures by consistently delivering health-aware products. The key to the brand's success lies in the superior product quality of Tata Salt.
The biocon pharmaceutical ppt is majorly focused on the background, the history and revenue, EBITDA, number of employees working, the segment, turnover of the company of FY16 and SWOT analysis.
Aarti Drugs Limited (ADL), incorporated in 1984 is part of Rs 3,000 crore Aarti Group of
Industries and is engaged in manufacturing and sale of Active pharmaceutical ingredients
(APIs), advanced intermediates and specialty chemicals. ADL manufactures drugs in
therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, sedatives,
anti-depressant, anti-diarrhea and anti-inflammatory.
In Aarti Drugs we get a bulk drugs manufacturer with steady growth across the years,
continuously improving performance on various financial parameters, good dividend
yield of more than 5% and low valuations of 5 times earnings and EV/EBIT of 5.28.
Besides, what instills further confidence in the stock is the fact that promoters of the
company have been continuously increasing their stake with regular purchases from open
market. Two years back promoters had 54.83% stake in the company and the same now
stands increased to 59.65%.
Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 b...Ajjay Kumar Gupta
Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023: Investment Opportunity for Startups and Entrepreneurs, Medications, Drugs and Pharmaceuticals, Cephalexin Monohydrate, Ampicilin Trihydrate, Ibuprofen Manufacturing Plant, Detailed Project Report, Profile, Business Plan, Industry Trends, Market Research, Survey, Manufacturing Process, Machinery, Raw Materials, Feasibility Study, Investment Opportunities, Cost and Revenue, Plant Economics, Production Schedule, Working Capital Requirement, Plant Layout, Process Flow Sheet, Cost of Project, Projected Balance Sheets, Profitability Ratios, Break Even Analysis
Production of active pharmaceutical ingredients is a highly sophisticated and technically demanding process. The global active pharmaceutical ingredient market is surging due to the increased demand for pharmaceutical drugs, which in turn is driven by aging population, increasing prevalence of chronic diseases such as cancer, diabetes, cardiovascular, neurological and infectious diseases among others. The global Active Pharmaceutical Ingredient market for was valued at US$ 12.9 bn in 2014 and is estimated to reach US$ 21.9 billion by 2023 at a CAGR of 6.3% from 2015 to 2023.
See more
https://goo.gl/dwgi0H
https://goo.gl/qRJmnp
https://goo.gl/t2QFiI
Contact us:
Niir Project Consultancy Services
106-E, Kamla Nagar, Opp. Spark Mall,
New Delhi-110007, India.
Email: npcs.ei@gmail.com , info@entrepreneurindia.co
Tel: +91-11-23843955, 23845654, 23845886, 8800733955
Mobile: +91-9811043595
Website :
http://www.niir.org
http://www.entrepreneurindia.co
Tags
Active Pharmaceutical Ingredients Manufacturing, Active Pharmaceutical Ingredients, API Manufacture in India, API Manufacturing, Manufacturing of Active Pharmaceutical Ingredients, API Manufacturing Industry, API Manufacturing Plant, Active Pharmaceutical Ingredient Manufacture, Manufacture of Active Pharmaceutical Ingredients, Manufacturing of Active Pharmaceutical Ingredients, Active Pharmaceutical Ingredient Manufacturing Plant, Processing of Active Pharmaceutical Ingredient, Active Pharmaceutical Ingredients Plant, Preparation of Active Pharmaceutical Ingredients (API), Active Pharmaceutical Ingredients Industry, Production of Active Pharmaceutical Ingredients (API), Active Pharmaceutical Ingredients Manufacturing Unit, Plans to Set Up API (Active Pharmaceutical Ingredients) Manufacturing Project, Active Pharmaceutical Ingredient Manufacturing Process, Active Pharmaceutical Ingredients Production, Production Process of API, Active Pharmaceutical Ingredient (API) Production, API Manufacturing Process, Business Planning for Active Pharmaceutical Ingredients Manufacturing, Business Plan for Manufacturing Active Pharmaceutical Ingredient, Start Active Pharmaceutical Ingredient (API) Production Business, Plant for Production of Active Pharmaceutical Ingredient
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
2. COMPANY
OVERVIEW
Abbott India Ltd is one of the largest MNC
pharma companies operating in India. It is a
subsidiary of Abbott Laboratories of USA.
Abbott Laboratories held 75% stake in Abbott
India as on 31 March 2018. The company is
engaged in the discovery development
manufacture and marketing of
pharmaceutical diagnostic nutritional and
hospital products. They are having their
presence in both OTC drugs and formulations.
Their manufacturing facilities are located at
Verna in Goa.
Abbott India Ltd.is a healthcare company that
discovers, develops, manufactures and
markets various products in area of
Anesthesia, Animal Health, Anti-Infectives,
Cardiovascular, Diabetes Care, Hematology,
Immunodiagnostics and Clinical Chemistry,
Immunology, Metabolics, Molecular,
Neuroscience, Nutrition, Oncology, Pain Care,
Point of Care, Renal Care, Vascular, Virology.
The company has in-house development and
medical teams to undertake product and
clinical development tailored to the needs of
the Indian market.
02
Research Insight-2
Rs 15511.05
CURRENT MARKET PRICE
BSE
Stock Data
Value Parameters
4. SHAREHOLDING
PATTERN
Shareholding Summary Statement - Abbott India Ltd.
Shareholding Pattern - Abbott India Ltd.
04
Foreign Promoter
75%
General Public
14.6%
N Banks Mutual Funds
4.8%
Financial Institutions
1.3%
Others
2.7%
Research Insight-2
5. MANAGEMENT
05
Research Insight-2
Name Designation Qualification
Experience
(inyears)
Anisha
Motwani
Independent
Director
MBA / B.Sc. 28
Anil
Joseph
Managing
Director
MBA(Marketing & HR) /
B.Sc. in Mathematics
25
Shalini
Kamath
Independent
Director
MBA (HR &
Marketing)
23
Sudarshan
Jain
Independent
Director
MBA / B.Sc. in
Physics
35
Munir
Shaikh
Chairman & CEO
ICAEW (Institute of
Chartered Accountants in
England and Wales
52
Ambati
Venu
Non-Executive
Director
MBA / BE (Mechanical
Enginnering)
24
Kaiyomarz
Marfatia
Non-Executive
Director
LLB (Qualified law
professional)
36
Rajiv
Sonalker
Whole-time
Director & CFO
ICAI (Institute of
Chartered Accountants
of India)
28
6. SWOT ANALYSIS
06
Research Insight-2
Strong distribution network – Over the years Abbott has built a
reliable distribution network that can reach majority of its potential
market.
Strong Brand Portfolio – Over the years Abbott has invested in
building a strong brand portfolio. The SWOT analysis of Abbott just
underlines this fact. This brand portfolio can be extremely useful if
the organization wants to expand into new product categories.
Skilled Employees Base - Abbott India Ltd employs over 2,600 people
and reaches customers through a wide network of 35 distribution
points, catering to over 4,500 stockists and 150,000 retail outlets.The
company has over 100 employees at a state-of-the-art formulation
plant at Verna, Goa.
Strong dealer community – It has built a culture among distributor &
dealers where the dealers not only promote company’s products but
also invest in training the sales team to explain to the customer how
he/she can extract the maximum benefits out of the products.
Merger & Acquisition: Successful track record of integrating
complimentary firms through mergers & acquisition. It has
successfully integrated number of technology companies in the past
few years to streamline its operations and to build a reliable supply
chain.
STRENGTHS of Abbott India Ltd. – Internal Strategic
Factors
7. SWOT ANALYSIS
07
Research Insight-2
Good Returns on Capital Expenditure – Abbott Laboratories is
relatively successful at execution of new projects and generated good
returns on capital expenditure by building new revenue streams.
Superb Performance in New Markets – Abbott Laboratories has built
expertise at entering new markets and making success of them. The
expansion has helped the organization to build new revenue stream
and diversify the economic cycle risk in the markets it operates in.
Strong Experience in the industry - experience is the most important
thing not only in the medical industry but also in any industry you can
imagine of. As it has been operating for 129 years; it has developed a
strong experience base. Abbott can apply this experience for its
future investment and to introduce innovative products.
STRENGTHS of Abbott India Ltd. – Internal Strategic
Factors
2016 2017 2018 2019 2020
500,000
400,000
300,000
200,000
100,000
0
10.9%
10.7%
14.3%
11.1%
14.0%
420753379189341549296020269623
REVENUE ( Rs in LAKHS)
Revenue Growth 10.9%
8. SWOT ANALYSIS
08
Research Insight-2
Limited success outside core business – Even though Abbott is one of
the leading organizations in its industry it has faced challenges in
moving to other product segments with its present culture.
Organization structure is only compatible with present business
model thus limiting expansion in adjacent product segments.
Not very good at product demand forecasting leading to higher rate
of missed opportunities compare to its competitors. One of the reason
why the days inventory is high compare to its competitors is that
Abbott is not very good at demand forecasting thus end up keeping
higher inventory both in-house and in channel.
Need more investment in new technologies. Given the scale of
expansion and different geographies the company is planning to
expand into, Abbott needs to put more money in technology to
integrate the processes across the board. Right now the investment in
technologies is not at par with the vision of the company.
Low R&D Expenses - after the year 2010, It has decreased its budget
on research & development. It may result to weaken R&D
department.
Financial planning is not done properly and efficiently. The current
asset ratio and liquid asset ratios suggest that the company can use
the cash more efficiently than what it is doing at present.
WEAKNESSES of Abbott India Ltd. – Internal Strategic
Factors
9. SWOT ANALYSIS
09
Research Insight-2
New environmental policies – The new opportunities will create a
level playing field for all the players in the industry. It represent a
great opportunity for Abbott Laboratories to drive home its advantage
in new technology and gain market share in the new product
category.
Lower inflation rate – The low inflation rate bring more stability in
the market, enable credit at lower interest rate to the customers of
Abbott.
New trends in the consumer behavior can open up new market for the
Abbott. It provides a great opportunity for the organization to build
new revenue streams and diversify into new product categories too.
Abbott offers innovative products & services. The most products
across the medical devices and diagnostics. The nutrition product
division include Similac, Ensure, Pedialyte, Glucerna, FreeStyle Libre,
ZonePerfect, MitraClip, & i-STAT.
Stable free cash flow provides opportunities to invest in adjacent
product segments. With more cash in bank the company can invest in
new technologies as well as in new products segments. This should
open a window of opportunity for Abbott Laboratories in other
product categories.
OPPORTUNITIES of Abbott India Ltd. – External
Strategic Factors
10. SWOT ANALYSIS
10
Research Insight-2
Intense competition – Stable profitability has increased the number
of players in the industry over last two years which has put downward
pressure on not only profitability but also on overall sales.
Growing strengths of local distributors also presents a threat in some
markets as the competition is paying higher margins to the local
distributors.
No regular supply of innovative products – Over the years the
company has developed numerous products but those are often
response to the development by other players. Secondly the supply of
new products is not regular thus leading to high and low swings in
the sales number over period of time.
Shortage of skilled workforce in certain global market represents a
threat to steady growth of profits for Abbott Laboratories in those
markets.
Exchange Rate Fluctuation - as it is a global company, it sells its
products and buys raw materials from other countries as well. A
negative change in the exchange rate may bring harm to its profit
growth.
THREATS of Abbott India Ltd. – External Strategic
Factors
11. COMPETITIVE
ANALYSIS
11
Research Insight-2
Sun Pharmaceutical Industries Limited is an Indian multinational
pharmaceutical company headquartered in Mumbai, Maharashtra, that
manufactures and sells pharmaceutical formulations and active
pharmaceutical ingredients (APIs) primarily in India and the United
States. The company offers formulations in various therapeutic areas,
such as cardiology, psychiatry, neurology, gastroenterology and
diabetology. It also provides APIs such as warfarin, carbamazepine,
etodolac, and clorazepate, as well as anti-cancers, steroids, peptides,
sex hormones, and controlled substances.
0 25,000 50,000 75,000 100,000 125,000
Sun Pharma
Dr Reddys Labs
Divis Labs
Cipla
Aurobindo Pharm
Torrent Pharma
Lupin
Cadila Health
Abbott India
Alkem Lab
..............Market Cap. (Rs. cr.).................
MAJOR COMPETITORS
12. COMPETITIVE
ANALYSIS
11
Research Insight-2
Sun Pharmaceutical Industries Limited is an Indian multinational
pharmaceutical company headquartered in Mumbai, Maharashtra, that
manufactures and sells pharmaceutical formulations and active
pharmaceutical ingredients (APIs) primarily in India and the United
States. The company offers formulations in various therapeutic areas,
such as cardiology, psychiatry, neurology, gastroenterology and
diabetology. It also provides APIs such as warfarin, carbamazepine,
etodolac, and clorazepate, as well as anti-cancers, steroids, peptides,
sex hormones, and controlled substances.
0 25,000 50,000 75,000 100,000 125,000
Sun Pharma
Dr Reddys Labs
Divis Labs
Cipla
Aurobindo Pharm
Torrent Pharma
Lupin
Cadila Health
Abbott India
Alkem Lab
..............Market Cap. (Rs. cr.).................
MAJOR COMPETITORS
13. CONCLUSION
13
Research Insight-2
As one of the leading organizations in its industry, Abbott
Laboratories has numerous strengths that help it to thrive in the
market place. These strengths not only help it to protect the
market share in existing markets but also help in penetrating new
markets.
Certain capabilities or factors of an organization can be both a
strength and weakness at the same time. This is one of the major
limitations of SWOT analysis . For example changing
environmental regulations can be both a threat to company it can
also be an opportunity in a sense that it will enable the company
to be on a level playing field or at advantage to competitors if it
able to develop the products faster than the competitors.